Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Maze Therapeutics, Inc. (MAZE) had Weighted-Average Shares Outstanding (Diluted) of 42.98M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-34.57M |
|
-- |
|
-- |
|
$38.06M |
|
$-38.06M |
|
$3.49M |
|
$-34.57M |
|
$-34.57M |
|
$-34.57M |
|
$-34.57M |
|
$-34.57M |
|
$-34.57M |
|
$-38.06M |
|
$-37.56M |
|
42.98M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
42.98M |
$-0.47 |
|
$-0.47 |
|
| Balance Sheet Financials | |
$349.72M |
|
$5.04M |
|
$47.41M |
|
$397.13M |
|
$22.56M |
|
-- |
|
$19.61M |
|
$42.16M |
|
$354.97M |
|
$354.97M |
|
$354.97M |
|
49.34M |
|
| Cash Flow Statement Financials | |
$-111.94M |
|
$-170.96M |
|
$275.34M |
|
$197.90M |
|
$190.34M |
|
$-7.57M |
|
$16.40M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
15.50 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-112.73M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-9.74% |
|
-9.74% |
|
-8.70% |
|
-9.74% |
|
$7.19 |
|
$-2.62 |
|
$-2.60 |
|